PRKAA2 and metabolic disease: Future studies will be needed to determine whether impairments in Ala/NH3 metabolism and AMPK induction contribute to susceptibility to metabolic disease, and to define whether intermittent administration of Ala could be used therapeutically to enhance glucose tolerance.